Results 151 to 160 of about 13,218 (205)

Anti-TSLP Drug

Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology
openaire   +2 more sources

Group 2 innate lymphoid cells: Where are we 15 years out? [PDF]

J Allergy Clin Immunol
Doherty TA.
europepmc   +1 more source

Effects of Tezepelumab in "United Airway Disease" (Asthma and CRSwNP). [PDF]

Case Rep Pulmonol
Lupia C, Piazzetta GL, Pastore D, Lobello N, Preianò M, Chiarella E, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +9 more
europepmc   +1 more source

ERS Congress 2025: highlights from the Airway Diseases Assembly. [PDF]

ERJ Open Res
Cefaloni F, Booth S, Healey CE, Ioannidou D, Schiavi E, Bonini M, Nieto-Fontarigo JJ, Principe S, Braunstahl GJ, Mathioudakis AG, Pobeha P, Schleich F, Bossios A, Beech A.   +13 more
europepmc   +1 more source

Cycling biologic therapy with tezepelumab and mepolizumab for eosinophilic otitis media and eosinophilic pneumonia in a patient with asthma. [PDF]

J Allergy Clin Immunol Glob
Matsuno O, Kawashima K, Hanada Y, Wibowo T, Ishida Y, Ogata A.   +5 more
europepmc   +1 more source

The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management. [PDF]

Immunotargets Ther
Bertin L, Caldart F, Barchi A, Seregni N, Pasta A, Calabrese F, Marabotto E, Mari A, Farah A, Sirinic E, Sorge A, Ghisa M, Chahuán J, Savarino V, Savarino EV.   +14 more
europepmc   +1 more source

Eosinophilic Esophagitis: Mechanisms of Disease and Approach to Treatment. [PDF]

Curr Allergy Asthma Rep
Gautam R, Ruffner MA.
europepmc   +1 more source

Potential of alarmin-targeted bispecific and combination therapies in airway disease. [PDF]

Front Allergy
Komori HK, Ortega H.
europepmc   +1 more source

Baicalein mitigates epithelial barrier impairment and microbiota dysbiosis in allergic asthmatic mice via the gut‑lung axis. [PDF]

Chin Med
Lu Y, Rong X, Wei L, Yang J, Zhang K, Tan Y, Zhao N, He X, Lu C, Li L.   +9 more
europepmc   +1 more source